Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin

Shares of rare disease therapy developer Inozyme Pharma INZY.O rise 177.46% to $3.94, near the six-month high of $3.96

BioMarin Pharma BMRN.O says that it has entered into an agreement to buy Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of around $270 million

*BMRN shares up 1.1% at $5.94

The deal is expected to close in Q3 2025

The deal will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed to treat a rare genetic disorder affecting blood vessels, soft tissues and bones, BMRN says

Including session's moves, INZY up 42.4%, BMRN down 11.2% YTD